Amgen Inc.AMGN

Healthcare
Neutral

ASignal's systematic analysis rates AMGN as Neutral. Amgen Inc. has a market cap of $209.21B, a P/E of 26.94, a 21.0% net margin, and 5.8% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Aug 1, 2026

The case on AMGN

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong operating and gross margins (33.80% and 71.44%) indicating pricing power and cost efficiency
  • Positive free cash flow of $7.44B supporting financial flexibility
  • MACD above signal line with expanding histogram, confirming bullish momentum
  • Price trading above both SMA20 and SMA50, indicating uptrend
  • Forward P/E of 16.54x suggests better valuation relative to current P/E
VS
Bear case
  • High debt-to-equity ratio of 6.24x, raising financial risk concerns
  • RSI at 67.96 – approaching overbought territory
  • Price near upper Bollinger Band (387.37), suggesting potential pullback
  • PEG ratio of 2.06x indicates overvaluation relative to growth rate
  • Low Reddit mentions (1) signaling weak retail investor interest

Key facts

Sector
Healthcare
Market cap
$209.21B
P/E ratio
26.94
Gross margin
71.4%
Net margin
21.0%
Rev growth YoY
5.8%
Price (Jul 30, 2026)
$387.64

Peers

Clustered with AMGN by analysis-profile similarity.

Subscriber-only

See the full verdict on AMGN

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes AMGN

Most investors never get a second opinion, let alone several. ASignal runs AMGN past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Amgen Inc. (AMGN) Stock Analysis - ASignal rates it Neutral